Spotlight on quetiapine in bipolar depression.

Abstract

Quetiapine (Seroquel) is the only atypical antipsychotic approved in the US for use as monotherapy in both bipolar mania and depression, offering potential compliance advantages. Monotherapy with oral quetiapine 300 mg/day is effective in the treatment of patients with bipolar I or II depression. Rapid and sustained improvements in depressive and anxiety symptoms are seen with quetiapine, as well as improvements in health-related quality of life. Quetiapine is generally well tolerated in bipolar depression and is not associated with an increased risk of treatment-emergent mania. Thus, despite the current lack of data from active comparator trials, quetiapine monotherapy should be considered a first-line option for the acute treatment of bipolar depression.

• Authors: Gillian M Keating, Dean M Robinson
• Journal: CNS drugs (CNS Drugs) Vol. 21 Issue 8 Pg. 695-7 ( 2007) ISSN: 1172-7047 [Print] New Zealand
• PMID: 17630822 (Publication Type: Journal Article, Review)

Chemical References

• Antipsychotic Agents
• Dibenzothiazepines
• Quetiapine Fumarate

Topics

• Antipsychotic Agents (therapeutic use)
• Bipolar Disorder (drug therapy, psychology)
• Dibenzothiazepines (therapeutic use)
• Humans
• Quality of Life
• Quetiapine Fumarate